Literature DB >> 217524

Prolactin receptors in human breast carcinoma.

R K Partridge, R Hähnel.   

Abstract

A preliminary investigation into prolactin receptors in human breast carcinomas provided strong evidence that specific binding of prolactin was occurring in at least three of the nine specimens examined (eight human breast carcinomas and one scalp metastasis). These "prolactin receptor positive" tumors were all from premenopausal patients. Three of the tumors of postmenopausal women also suggested the occurrence of specific prolactin binding but, as saturation of the receptors had not been achieved in these assays, the results require confirmation. Some general trends in the binding characteristics of the tumors of premenopausal and postmenopausal patients were also observed.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 217524     DOI: 10.1002/1097-0142(197902)43:2<643::aid-cncr2820430235>3.0.co;2-c

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  Expression of prolactin receptors in normal, benign, and malignant breast tissue: an immunohistological study.

Authors:  S Gill; D Peston; B K Vonderhaar; S Shousha
Journal:  J Clin Pathol       Date:  2001-12       Impact factor: 3.411

2.  Total prolactin binding sites in human breast cancer biopsies.

Authors:  J P Peyrat; D Dewailly; J Djiane; P A Kelly; B Vandewalle; J Bonneterre; J Lefebvre
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

3.  Characterization of prolactin receptors in human breast cancer.

Authors:  J P Peyrat; J Djiane; P A Kelly; B Vandewalle; J Bonneterre; A Demaille
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872

4.  Expression and prognostic significance of lysozyme in male breast cancer.

Authors:  Carlos Serra; Francisco Vizoso; Lorena Alonso; Juan C Rodríguez; Luis O González; María Fernández; María L Lamelas; Luis M Sánchez; José L García-Muñiz; Aniceto Baltasar; Justo Medrano
Journal:  Breast Cancer Res       Date:  2002-08-27       Impact factor: 6.466

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.